Developmental and Epileptic Encephalopathies (DEE) - Epidemiology Forecast - 2034

Key Highlights

• In 2020, the total diagnosed prevalent cases of DEE in the US were ~141,310
• In 2023, the diagnosed prevalent cases of Lennox Gastaut Syndrome in the US were ~50,090.
• In 2023, the total diagnosed prevalent cases of Early Myoclonic Encephalopathy in Japan were around 20, where as the diagnosed prevalent cases of Epileptic Encephalopathy with continuous spike-and-wave during sleep were around 38.

The “Developmental and Epileptic Encephalopathy (DEE)- Epidemiology Forecast - 2034” report delivers an in-depth understanding of DEE, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

DEE Understanding and Treatment Algorithm

DEE Overview

Developmental and Epileptic Encephalopathy refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. Developmental encephalopathy implies that developmental delays are the direct result of the underlying cause of their epilepsy. In addition, some children with DEEs also have epileptic encephalopathy due to very frequent seizures and markedly abnormal electroencephalographs, which may substantially worsen developmental problems.

The syndromes of epileptic encephalopathies with onset in the neonatal period, infancy, and early childhood include Dravet syndrome (severe myoclonic epilepsy in infancy), LGS, CDKL5 Deficiency Disorder (CDD), TSC, DUP15q syndrome, SCN2A-DEE, SCN8A-DEE, KCNQ2-DEE, KCNQ3-DEE, Angelman syndrome, Landau-Kleffner Syndrome (LKS), Early Myoclonic Encephalopathy, KCNT1-DEE, Rett syndrome, Ohtahara syndrome, PCDH19, EE w/continuous spike-wave, Myoclonic Atonic Epilepsy, Ring20 and others.

DEE Diagnosis

Diagnosing epilepsy is not always easy. The doctor usually considers the person’s background and medical history, conducts a physical examination, as well as refers them for tests and investigations, to assess the type of seizures and make a diagnosis. Medical tests that are used in the diagnosis of epilepsy include blood tests, EEG (electroencephalogram), CT scan (Computerized Tomography), and/or an MRI (Magnetic Resonance Imaging).

Tests may be performed to: confirm the doctor’s suspicion, determine the type of seizure or epilepsy, determine the most appropriate treatment for the child’s condition, determine the underlying cause of the child’s epilepsy, monitor the treatment of the child’s epilepsy, and assess associated mental health or behavioral problems.

DEE Epidemiology

The DEE epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of DEE, DEE Cases by subtypes in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

• The total number of diagnosed prevalent cases of DEE in the 7MM was nearly 284,000 cases in 2023 and are projected to increase during the forecasted period.
• Lennox-Gastaut syndrome and tuberous sclerosis complex asscociated epilepsy are the largest contributors to the overall DEE pool. The prevalent cases of DEE in the United States were nearly 50,000 for Lennox-Gastaut syndrome and nearly 47,100 for tuberous sclerosis complex with epilepsy in 2023.
• The total number of cases in EU4 and the UK for DEE was estimated to be nearly 104,000 cases in 2023.
• Among EU4 and the UK, the highest number of cases for DEE was found in Germany which was estimated to nearly 34% of cases in EU4 and the UK in 2023.

Scope of the Report

DEE Report Insights

• Patient Population
• Country-wise Epidemiology Distribution

DEE Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• DEE Epidemiology Segmentation

FAQs

• What are the disease risks, burdens, and unmet needs of DEE? What will be the growth opportunities across the 7MM concerning the patient population with DEE?
• What is the historical and forecasted DEE patient pool in the US, EU4 (Germany, France, Italy, and Spain) the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.